X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Lead Product(s): Chondroitin Sulfate
Therapeutic Area: Musculoskeletal Product Name: CSbioactive
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2021
Details:
The study, conducted in a rabbit model of osteoarthritis, set out to evaluate the effects of b-2Cool native type II collagen in combination with CS b-Bioactive chondroitin sulphate, glucosamine hydrochloride and Mobilee® which is a rooster comb extract rich in hyaluronic acid.
Lead Product(s): Undenatured Type II Collagen,Chondroitin Sulfate,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Mobilee
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2020
Details:
Under the terms of the agreement, Bayer Animal Health will distribute and market selected products from Bioiberica´s Companion Animal Health portfolio in eight countries.
Lead Product(s): Chondroitin Sulfate,Glucosamine,Hyaluronic Acid
Therapeutic Area: Musculoskeletal Product Name: Condrovet
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bioiberica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Bioiberica is a global life science company committed to improving the health & wellbeing of people, animals & plants.
